Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | SCD | O00767 | 3/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | PRKCB | P05771 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCH | P24723 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.44 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150796 | 0.83 | DRD2 (0.68) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL30102638 | 0.82 | DRD2 (0.70) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL3144674 | 0.82 | DRD2 (0.70) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL7141854 | 0.82 | DRD2 (0.74) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL3144999 | 0.82 | DRD2 (0.66) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL28189418 | 0.81 | DRD2 (0.65) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL367111 | 0.81 | DRD2 (0.63) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL29423860 | 0.81 | DRD2 (0.63) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL3141317 | 0.81 | DRD2 (0.64) | DRD2SLC6A4OPRM1OPRD1OPRK1 | |
| Fluorobenzene SCHEMBL27494806 | 0.80 | DRD2 (0.53) | DRD2SLC6A4HTR2AHTR7SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-9226930-B2 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226930-B2 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2015-05-21 | — | — | US | disclosed |
| EP-1449529-B1 | Protein Kinase C Inhibitors | LILLY CO ELI (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2007137590-A1 | SERTINDOLE FOR THE PREVENTIVE TREATMENT OF SUICIDAL BEHAVIOUR | H. LUNDBECK A/S (DK) | 2007-12-06 | — | — | WO | disclosed |
| EP-0817627-B1 | PROTEIN KINASE C INHIBITORS | LILLY CO ELI (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1449529-A1 | Protein Kinase C Inhibitors | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-0817627-A1 | PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5672618-A | TREATING DIABETIC COMPLICATIONS | ELI LILLY AND COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| US-5668152-A | BIS/INDOLE/-SUBSTITUTED MALEIMIDES, ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5661173-A | ADMINISTERING AN ENZYME INHIBITOR TREATING DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| US-5545636-A | TREATING DIABETES MELLITUS | ELI LILLY AND COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| WO-1995017182-A1 | PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | DRD2 202/4885SLC6A4 198/4885OPRM1 251/4885 |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | DRD2 202/4885SLC6A4 198/4885OPRM1 251/4885 |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | DRD2 147/4885SLC6A4 208/4885OPRM1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.